The β 2 -adrenergic receptor (β 2 AR) has been a model system for understanding regulatory mechanisms of G-protein-coupled receptor (GPCR) actions and plays a significant role in cardiovascular and pulmonary diseases. Because all known β-adrenergic receptor drugs target the orthosteric binding site of the receptor, we set out to isolate allosteric ligands for this receptor by panning DNA-encoded small-molecule libraries comprising 190 million distinct compounds against purified human β 2 AR. Here, we report the discovery of a small-molecule negative allosteric modulator (antagonist), compound 15 [([4-((2S)-3-(((S)-3-(3-bromophenyl)-1-(methylamino)-1-oxopropan-2-yl)amino)-2-(2-cyclohexyl-2-phenylacetamido)-3-oxopropyl)benzamide], exhibiting a unique chemotype and low micromolar affinity for the β 2 AR. Binding of 15 to the receptor cooperatively enhances orthosteric inverse agonist binding while negatively modulating binding of orthosteric agonists. Studies with a specific antibody that binds to an intracellular region of the β 2 AR suggest that 15 binds in proximity to the G-protein binding site on the cytosolic surface of the β 2 AR. In cell-signaling studies, 15 inhibits cAMP production through the β 2 AR, but not that mediated by other Gs-coupled receptors. Compound 15 also similarly inhibits β-arrestin recruitment to the activated β 2 AR. This study presents an allosteric small-molecule ligand for the β 2 AR and introduces a broadly applicable method for screening DNA-encoded small-molecule libraries against purified GPCR targets. Importantly, such an approach could facilitate the discovery of GPCR drugs with tailored allosteric effects.
G-protein-coupled receptor | β 2 -adrenergic receptor | allosteric modulator | DNA-encoded small-molecule library | drug discovery G -protein-coupled receptors (GPCRs), also known as seven transmembrane receptors, represent the largest family of cellular receptors and the most common therapeutic drug targets. Accordingly, GPCRs are the subject of intensive research, both in academia and the pharmaceutical industry, aimed at elucidating their structures, detailed mechanisms of action, and discovery of novel ligands with therapeutic potential (1) (2) (3) . To date, the overwhelming majority of GPCR drugs target the orthosteric site on the receptors. This is the binding site of endogenous ligands, which generally faces the extracellular surface of the receptor (4, 5) . However, in recent years, functionally active allosteric ligands, which bind outside the orthosteric site, have also been discovered. Allosteric ligands that augment or reduce the binding affinity and/or functional responses of orthosteric ligands are referred to as positive or negative allosteric modulators (PAMs or NAMs), respectively (5) . Such allosteric ligands hold great therapeutic promise due to their enhanced selectivity among receptor subtypes compared with orthosteric drugs targeting the same subtype. The first approved allosteric drugs for GPCRs target chemokine CCR5 (6) and calcium-sensing receptors (7) to treat HIV infections and hyperparathyroidism, respectively, with many more modulators in preclinical development. Allosteric modulators also have great utility as tool compounds in biophysical studies as they are able to lock receptors into specific conformations by virtue of their cooperative interactions with orthosteric ligands (4, 5) .
In the past, screening for GPCR ligands, either allosteric or orthosteric, has been cumbersome and labor-intensive. Such screens have generally been based on the functional ability of compounds to either stimulate or block receptor-mediated activities in whole-cell-based settings (8) . A more rapid and efficient approach is to use interaction-based methods for initial screening wherein large libraries of molecules are panned against the target receptor. However, until recently, such libraries have consisted only of macromolecules such as phage-displayed antibodies (9, 10)
Significance
The present study reports the discovery of a small-molecule negative allosteric modulator for the β 2 -adrenergic receptor (β 2 AR) via in vitro affinity-based iterative selection of highly diverse DNA-encoded small-molecule libraries. Characterization of the compound demonstrates its selectivity for the β 2 AR and that it negatively modulates a wide range of receptor functions. More importantly, our findings establish a generally applicable, proof-of-concept strategy for screening DNA-encoded small-molecule libraries against purified G-protein-coupled receptors (GPCRs), which holds great potential for discovering therapeutic molecules.
or RNA aptamers (11) . Another approach, which has not yet been widely applied, is screening of DNA-encoded small-molecule libraries (DELs). In this approach, remarkably large combinatorial libraries consisting of up to billions of small-molecule compounds are displayed on DNA fragments that serve as barcodes for their subsequent identification (12, 13) . In the past few years, application of the DEL screening technology for soluble proteins has produced inhibitors against cancer and immune disorders and against therapeutic targets. These are protein kinases such as Src, MK2, Akt3, Pim1, Aurora A kinase, p38 mitogen-activated protein (MAP) kinase, and antiapoptotic protein Bcl-xL (14, 15) . Expanding such technology to GPCRs has the potential to yield both orthosteric and allosteric ligands. However, its application to GPCR screening has been challenging, largely because of difficulties associated with preparing appropriate receptor targets as well as the membranebound nature of the receptors, which can lead to nonspecific interactions. To date, identification of a compound that inhibits the NK 3 tachykinin receptor by screening against the receptor expressed in whole cells represents the only successful application of DEL technology against GPCRs (16) .
The β 2 -adrenergic receptor (β 2 AR) has served as the model system for molecular studies of ligand-binding GPCRs for over 40 y (1) and plays a significant role in cardiovascular and pulmonary diseases. So-called "β-blockers," which are orthosteric antagonists of the receptor, are mainstays of cardiovascular medicines used to treat a wide variety of illnesses (17) (18) (19) . On the other hand, β-agonists have proven very effective against asthma (20) . However, all known β-adrenergic ligands act orthosterically; thus, it is possible that allosteric modulators would possess enhanced therapeutic efficacy, selectivity, or even unique therapeutic properties such as signaling bias. Such ligands would also facilitate the isolation and characterization of specific receptor conformations for biophysical studies. Accordingly, here we set out to isolate allosteric ligands for the β 2 AR using DELs. We report isolation of a small-molecule negative allosteric modulator (antagonist) for the β 2 AR and provide a detailed characterization of its pharmacological properties and interaction with the receptor.
Results
Isolation of Compound 15 from DELs. To identify unique chemotypes that bind at structurally relevant sites on the surface of β 2 AR, we screened DELs against purified, unliganded β 2 AR maintained in the detergent n-dodecyl-β-D-maltoside (DDM) (Fig. 1A and Fig.  S1 ). A similar beads-only selection was performed in parallel as a control. In total, we screened three libraries together containing approximately a total of 190 million unique compounds synthesized using a DNA-tagged, split-and-pool combinatorial chemical synthesis approach (Chemetics; Nuevolution). In each library, ∼5 × 10 13 molecules in total were used as input, and 1-7 × 10 7 molecules remained after screening. Relative quantification of the recovered compounds was achieved by a combination of PCR amplification and next-generation sequencing of eluted DNA barcodes, followed by computational decoding approaches. To refine the output and eliminate potential nonspecific binders, compounds that displayed less than a 260-to 470-fold increase in frequency from baseline as well as those that were observed in bead-only control selections were filtered from the dataset, leaving a total of 394 potential β 2 AR binders for further analysis (Table S1 ). These compounds were then clustered based on their structural similarity, and 16 putative hits were selected as representatives for these clusters. DNA-tagged versions of these 16 hits were resynthesized and screened individually to evaluate their influence on the binding affinity of orthosteric agonists in radioligand binding assays with membranes obtained from β 2 AR-overexpressing cells. One compound [4- 
, designated as compound "15" (Fig. 1B) , markedly decreased orthosteric agonist binding to the receptor and was thus selected for further characterization.
Characterization of Compound 15 for Its Binding to the β 2 AR. To further characterize the pharmacological properties of 15, we synthesized it in its DNA-free form (Fig. 1B) . We first performed competition binding experiments with the radioiodinated antagonist cyanopindolol ( 125 I-CYP) to evaluate the influence of 15 on the binding ability of orthosteric ligands to the β 2 AR reconstituted into high-density lipoprotein (HDL) (also known as nanodisc) particles (21) . We found that, although 15 had little to no influence on binding of 125 I-CYP, which is a neutral orthosteric antagonist of the β 2 AR, it robustly decreased the binding affinity of the agonist isoproterenol for the receptor in a dose-dependent fashion ( Fig. 2A) . Compound 15 caused the isoproterenol competition curve to shift to the right by close to one log (ninefold) at the maximal concentration tested. The half-maximal concentration of 15 for this shift was ∼1.9 μM (Fig. 2B ). On the other hand, when the inverse agonist [ To further confirm that 15 favors an inactive conformational state of the receptor, we assessed the extent of binding of an inactive conformation-specific β 2 AR single domain antibody [nanobody-60 (Nb60)] that binds to an intracellular region of the receptor (10, 22) . Contrary to the positive cooperativity predicted to occur between a negative allosteric modulator and Nb60 (22), we found a decrease in Nb60 binding to the receptor in the presence of 15 (Fig. 2E ). This suggests that 15 competes with Nb60 for binding to the receptor, and thus that their binding sites at least partially overlap, indicating that 15 binds to an intracellular region of the β 2 AR.
It has been well appreciated that allosteric transducers such as heterotrimeric G proteins or β-arrestins promote high-affinity agonist binding (10, 23, 24) . We also observed that 15 inhibited the high-affinity binding of a radiolabeled (25) that is promoted by either heterotrimeric Gs protein or β-arrestin1 (Fig. 2F ). This finding also suggests that 15 negatively modulates activation of the β 2 AR by agonists. Furthermore, the dose-dependent effects of 15 in β-arrestin were similar to each other (Fig. 2G ). We used Fab30, which stabilizes an active conformation of β-arrestin1 (26, 27) , to enhance the weak high-affinity 3 H-Fen binding signal induced by β-arrestin to levels comparable to those observed with G protein.
The EC 50 values obtained from the 15 dose-response curves for the two transducer-promoted signals were comparable (2.8 vs. 2.2 μM, respectively, for G protein and β-arrestin; Fig. 2G ). This suggests that 15 displays no strong "bias" between its inhibitory activities in the two transducer-induced high-affinity (Fig. 2D) . Taken all together, the results in Fig. 2 show that 15 behaves as a negative allosteric modulator for the β 2 AR, and suggest that it binds at the cytoplasmic surface of the receptor.
Functional Modulation of β 2 AR Activity by Compound 15. Next, we investigated the effects of 15 on β 2 AR function in cells by measuring G-protein-mediated cAMP production (28, 29) and β-arrestin recruitment to the receptor (29, 30) . Due to the high signal amplification of the G-protein activation assay compared with β-arrestin recruitment, to achieve comparable signaling outputs between the two, we used endogenously expressed β 2 AR in the reporter cells to measure cAMP production, but we used stably overexpressed β 2 V 2 R for monitoring β-arrestin recruitment. The β 2 V 2 R, a chimeric receptor with a V 2 R tail at the C terminus, displays stronger and more stable agonist-promoted β-arrestin binding than the native β 2 AR while retaining the pharmacological properties of the native β 2 AR (31). Compound 15 decreased the isoproterenol-stimulated responses in both assays ( Fig. 3 A and B) . We observed rightward shifts of the EC 50 values, as well as decreases in the maximal level of the stimulated responses in the presence of increasing concentrations of 15, indicating that 15 inhibits β 2 AR agonist-induced functional responses. Additionally, the extent of rightward shift of isoproterenol potency promoted by 15 was similar for both G-protein activation and β-arrestin recruitment to activated receptor. On the other hand, the decreases in the maximal response induced by 15 were more robust in β-arrestin recruitment than in cAMP production ( Fig. 3 A and B) . This likely is attributed to the differences in the sensitivity between the assays, as described before (29) , rather than to any biased activity of 15. Such unbiased inhibition of β 2 AR activity by 15 is consistent with the finding that 15 similarly inhibits the high-affinity binding of 3 H-Fen promoted by either transducer (G protein or β-arrestin) (Fig. 2G) . These results confirm that 15 modulates β 2 AR by antagonizing its agonist-induced activity.
We further validated that the inhibitory effect of 15 in functional assays was a result of specific inhibition at the receptor level and not due to nonspecific effects by testing 15 in other cell-based assays that have distinct readouts from the luminescence-based assays shown in Fig. 3 . We monitored the effect of 15 on cAMP production upon stimulation of the overexpressed β 2 AR using a fluorescence resonance energy transfer (FRET)-based biosensor, ICUE2 (32) . In this experiment, 15 caused a rightward shift in the EC 50 for isoproterenol-stimulated cAMP production (Fig. S2A) , consistent with that shown in Fig. 3A , albeit without changing the maximal response. This may be attributed to the increased amplification of the signal due to overexpression of the β 2 AR in this assay compared with the signal by the receptor expressed at endogenous levels in Fig. 3A . Similarly, we also confirmed the inhibitory effect of 15 on agonist-stimulated β-arrestin recruitment to the β 2 AR by assessing FRET signals between β 2 AR-YFP and CFP-β-arrestin2 (Fig. S2B) . We further confirmed the inhibitory effect of 15 on β 2 AR activation using an in vitro GTPase activity assay with the β 2 AR reconstituted into HDL particles together with purified Gs protein (Fig. S2C) . The 15-induced shift in the EC 50 for isoproterenol obtained in this in vitro assay is comparable to that observed in the cell-based assays, suggesting that 15 must readily penetrate cell membranes to bind to an intracellular region of the β 2 AR, which is suggested by the result in Fig. 2E .
Selective Inhibition of β 2 AR-Mediated Activities by Compound 15.
To confirm the selectivity of 15 for the β 2 AR, we performed functional assays to evaluate whether 15 inhibited activation of other members of the GPCR family closely or distantly related to the β 2 AR. First, we compared the extent of 15 blockade of agoniststimulated activities of β 2 AR with two other endogenously expressed Gs-coupled receptors in HEK-293 cells, the prostaglandin E2 (PGE2) and vasoactive intestinal peptide (VIP) receptors. Notably, 15 had no effect on cAMP production following stimulation of these receptors (Fig. S3 A and B) . Additionally, we looked at the specificity of 15 for the β 2 AR by assessing its inhibitory effect on β-arrestin recruitment to other receptors besides the chimeric β 2 AR (β 2 V 2 R). Here, we used the parental cell line stably expressing β-arrestin2 alone, and transiently expressed receptors indicated in Fig. 4 . First, we confirmed that the extent of 15-mediated inhibition of agonist-stimulated β-arrestin recruitment to the wild-type β 2 AR (Fig. 4A) is comparable to that obtained in the transiently expressed chimeric receptor, β 2 V 2 R (Fig. 4B) . On the other hand, following stimulation of the β 1 AR, a receptor closely related to the β 2 AR, 15 substantially inhibited the maximal response as well as the basal activity in a concentration-dependent manner, whereas no significant changes were observed in the EC 50 value (Fig.  4C) . We also observed significant, but much reduced, inhibitory effects of 15 on β-arrestin recruitment to the vasopressin V 2 receptor (V 2 R), which is also a Gs-coupled receptor (Fig. 4D) . In contrast to this, 15 only minimally inhibited agonist-induced β-arrestin recruitment to the VIPR, another Gs-coupled receptor. We observed only minimal decreases in the maximal response to stimulation with VIP without any change in the EC 50 value induced by 15 (Fig. 4E) , consistent with the result obtained in cAMP accumulation (Fig. S3B) . Furthermore, no significant inhibition by 15 was detected in β-arrestin recruitment to the Gq-coupled angiotensin II type 1 receptor (AT 1 R) (Fig. 4F) . To further assess the extent of the 15 inhibitory activities among different receptors, we quantified the level of 15-mediated decreases in the maximal response as well as shifts of the EC 50 value exhibited as fold shifts (Table S2 ). These results demonstrate that the inhibitory effect of 15 on agonist-stimulated responses is greatest for the β 2 AR and is substantially diminished in even closely related receptors such as β 1 AR.
To obtain further insights into the specificity of 15 for the β 2 AR, we examined its inhibitory activity on agonist-induced β-arrestin internalization. Unlike "class B" receptors, including the V 2 R and the AT 1 R whose tight interactions with β-arrestin allow for their cointernalization, "class A" receptors such as the β 2 AR have weaker β-arrestin interactions and are not cointernalized with β-arrestin (33) . Therefore, we examined the effect of 15 on this functional activity with the transiently expressed β 2 V 2 R (Fig. S4A) , V 2 R (Fig. S4B) , and AT 1 R (Fig. S4C) . The extent of β-arrestin internalization was monitored by measuring the amount of β-arrestin targeted to endosomes (34) . Results obtained in this assay are consistent with the inhibitory effects of 15 on β-arrestin recruitment to activated receptors as shown in Fig. 4 , which are summarized in Table S2 , further confirming the specificity of the modulating activity of 15 for the β 2 AR. We also investigated whether the NAM activity of 15 at the β 2 AR was dependent on the presence of a specific agonist at the orthosteric site (i.e., probe dependence). We performed this by monitoring Gs-mediated cAMP production and β-arrestin recruitment to the receptor in the presence of orthosteric probes ranging from full to weak partial agonists, including epinephrine, fenoterol, and clenbuterol (Fig. S5) as done with isoproterenol (Fig. 3) . We also compared competition binding of these agonists to the β 2 AR with 125 I-CYP in the presence of different concentrations of 15 ( Fig. 2A and Fig. S5) , which allowed us to assess the probe dependence of 15 among the agonists in the absence of transducer coupling. Table S3 shows the summary of quantified values in each assay, including the extent of 15-mediated decreases in the maximal response and shifts of the EC 50 value exhibited as fold shifts. Overall, 15 appears to display no significant probe dependence among the tested agonists. We observed that the extent of the EC 50 value shift by 15, which is consistent among the tested assays, follows the efficacy of the tested agonists. On the other hand, the magnitude of 15 inhibition of the maximal response is negatively correlated with the efficacy of these agonists.
Structure-Activity Relationships of Compound 15 Analogs at the β 2 AR.
To discern the structure-activity relationship (SAR) pattern for the allosteric modulation of 15 at the β 2 AR, we designed and synthesized a series of 15 derivatives (Table S4) . We assessed the ability of these derivatives to modulate β 2 AR functions in two different types of experimental settings. These were cell-based activity assays, including G-protein-mediated cAMP production and β-arrestin recruitment to the activated β 2 AR, as well as high-affinity binding of the agonist 3 H-Fen to the receptor induced by transducers, Gs or β-arrestin. To assist our SAR analyses, 15 was divided into three structural subunits, the methylbenzamide (region I), bromo-benzyl (region II), and cyclohexylmethyl-benzene (region III) regions, into each of which we introduced modifications. We found that the formamide group in region I (methylbenzamide) is an important determinant of functional properties of 15. Removal of this group on the phenyl ring (A1) led to a dramatic decrease in the inhibitory activity of 15 down to about 20% or less of its original activity. The same, but less severe, trend was observed when the position of this formamide group was changed from its original para-position to a meta-position (A2), which resulted in a ∼60% reduction of its original activity. In the case of region II (bromo-benzyl), removal of the electronegative atom bromine (A3) also caused variable but substantial attenuation of the inhibitory activity of 15 down to about 10-55%. Two other modifications in this region, replacement of bromine with fluorine, an atom of comparable electronegativity but smaller radius (A4), and introduction of additional bromine at the meta-position of the phenyl ring (A5) modestly decreased the functional effects of 15. Next, we evaluated the activity of derivatives with modifications on the aromatic ring in region III (cyclohexylmethyl-benzene). Interestingly, addition of a hydroxyl group to this ring at the para-position (A6) led to dramatic loss of inhibitory activity, while replacing the hydroxyl group at this position with a slightly hydrophobic methoxy group (A7) partially restored the inhibitory activity. This strongly suggests that the hydrophobic nature of this region is another important determinant for efficient interaction of 15 with the presumably hydrophobic portion of the putative binding site of 15 on the β 2 AR.
Discussion
We report here the discovery and characterization of a small molecule, compound 15, as an allosteric β-blocker. Compound 15 was derived from an in vitro affinity-based screening of DELs against the purified human β 2 AR. Compound 15 shares no structural or chemical similarities with known β 2 AR orthosteric ligands, and it does not compete with radiolabeled β 2 AR ligands for binding at the orthosteric site. On the other hand, it binds allosterically to the β 2 AR with low micromolar affinity. The compound negatively modulates the binding of agonists to the β 2 AR while it clearly displays positive cooperativity with an orthosteric inverse agonist. In addition, in cell-based functional assays, 15 displays robust inhibition of β 2 AR agonist-promoted, Gs-mediated cAMP generation as well as β-arrestin recruitment to the receptor. Together, these characteristics demonstrate that 15 allosterically binds to and stabilizes an inactive conformation of the β 2 AR, which are the classic hallmarks of a negative allosteric modulator (5, 35) .
A large number of orthosteric ligands for the β 2 AR have been developed, whereas before this study, no allosteric small-molecule β 2 AR ligand had been identified. The affinity-based screening strategy is an ideal way to identify allosteric ligands for a receptor, and DEL screening is an innovative strategy to perform affinitybased selections against targets that are isolated or expressed on whole cells (12) . Although this technique enables an unprecedented increase in the size of libraries that can be screened compared with conventional activity-based screening formats, its use has mostly been limited to soluble protein targets (12, 13) . Due to the inherent difficulty in isolating functional membrane proteins, this technique has been only rarely used to obtain ligands for GPCRs. To date, there has been only one report describing the discovery of a ligand for a GPCR from a DEL (16) . There, the recombinant NK 3 tachykinin receptor expressed on HEK-293 cells was used as a target in a whole-cell selection format to identify an inhibitor for the receptor (16) . Here, we have demonstrated that the DEL screening strategy can be successfully applied to the isolation of small-molecule ligands using a purified GPCR. Although our study was focused on isolating and characterizing β 2 AR allosteric ligands, this strategy could be used as well to isolate ligands that target orthosteric sites of GPCRs. Despite the power of this approach, predicting the functional outcomes of the isolated compounds remains empirical. However, in our in vitro purified receptor target system, it is highly feasible to bias the selections through differential display of the receptor in unique conformations (e.g., agonist vs. antagonist vs. no ligand in the orthosteric site) or in complex with signaling partners such as G proteins or β-arrestins. This should provide allosteric modulators with distinct properties (e.g., NAMs, PAMs, or even biased molecules for coupling to transducers, leading to signaling bias).
To date, pharmacological studies of GPCR allosteric modulation have been restricted to a few receptor families including muscarinic acetylcholine, adenosine, chemokine, and metabotropic glutamate receptors (5, 36) . Compared with orthosteric ligands, drugs targeting allosteric sites often display greater receptor subtype selectivity and therefore potentially reduce adverse side effects (4, 5) . This is presumably due to decreased evolutionary pressure at allosteric sites than at the orthosteric site of GPCRs (35) , leading to their greater divergence within a family. Moreover, multiple allosteric sites can exist on a given receptor (37) . In addition, allosteric GPCR modulators may have greater potential than orthosteric ligands to engender biased signaling through selective modulation of specific signaling pathways, for example, G-protein versus β-arrestin pathways (4).
Our SAR studies provide insights into key regions of 15 that must engage in contacts with the allosteric binding site on the β 2 AR to allow its functional modulation. We found some alterations, including complete deletions of the formamide group in region I and bromine in region II, lead to dramatic decreases in the functional activities of the parent compound, 15. We also observed a positive association between increased polarity of region III and loss of functional activity. This suggests that this region of the molecule might interface deep within the β 2 AR allosteric site to establish contacts with core hydrophobic residues.
As with other GPCRs, several putative allosteric sites on the β 2 AR have been recently proposed based on crystal structures (37) . Some are located at the intracellular face of the receptor; these are relatively large and can accommodate a wide range of compound sizes. Interestingly, most of the currently reported nonsmall-molecule β 2 AR allosteric modulators, such as nanobodies (10, 22, 38) and RNA aptamers (11) , bind to intracellular cavities that overlap with the G-protein binding site (39) . This appears to be true as well for 15 because it competes for β 2 AR binding with a nanobody (Nb60) that favors an inactive conformation and that binds to this intracellular region of the β 2 AR (22) . Although our findings suggest that 15 binds to the intracellular region of the β 2 AR, further SAR and structural studies at atomic-level resolution will be required to precisely define the site and mechanism of action, by which 15 acts as a NAM.
In summary, our study reports the discovery via in vitro affinity selection of a DEL against purified receptors and functional characterization of a β 2 AR-selective negative allosteric modulator. Our findings suggest that targeting GPCR allosteric sites with such combinatorial small-molecule libraries provides a powerful and efficient approach for developing highly selective ligands that can modulate a wide range of receptor's functional activities. Furthermore, our findings establish a proof-of-concept strategy using the DEL screening technique, which can be broadly applied to discover small molecules for other GPCRs.
Materials and Methods
Complete details and descriptions of the materials used; cell culture and transfections; expression and purification of the β 2 AR; purified β 2 AR-based DEL selection, quantitative PCR, and next-generation sequencing analysis; reconstitution of the β 2 AR into HDL particles; radioligand binding; ITC; ELISA; measurement of cAMP accumulation and in vitro GTPase activity; β-arrestin recruitment and β-arrestin endocytosis assays; data analyses; and synthesis and characterization of compounds are provided in SI Materials and Methods.
